April 15, 2020
Announcement no. 10
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INTO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Information to U.S. shareholders
This rights offering is made for the securities of a foreign company. The offer is subject to the disclosure requirements of a foreign country that are different from those of the United States. Financial statements included in the document, if any, have been prepared in accordance with foreign accounting standards that may not be comparable to the financial statements of United States companies.
It may be difficult for you to enforce your rights and any claim you may have arising under the federal securities laws, since the issuer is located in a foreign country, and some or all of its officers and directors may be residents of a foreign country. You may not be able to sue the foreign company or its officers or directors in a foreign court for violations of the U.S. securities laws. It may be difficult to compel a foreign company and its affiliates to subject themselves to a U.S. court's judgment.
Completion of rights issue and capital increase
By company announcement no. 6 of March 16, 2020, BioPorto A/S (“BioPorto” or the “Company”) announced the initiation of a right issue (the “Offering”) with pre-emptive subscription rights for the Company’s existing shareholders allowing for subscription of up to 24,992,054 new shares with a nominal value of DKK 1 each (the “New Shares”). By company announcement no. 8 of April 3, 2020, BioPorto announced that the Offering was fully subscribed. For technical reasons related to the number of subscription rights, the total share capital increase will be DKK 24,992,053.
Completion of the Offering
BioPorto has now received the full subscription amount and has today procured that the capital increase associated with the Offering of in total nominally DKK 24,992,053 has been registered with the Danish Business Authority.
The Offering results in gross proceeds for BioPorto of DKK 39,987,284.80 and expected net proceeds (gross proceeds less estimated related costs for the Company) of approximately DKK 37,500,000.
Admission to trading and official listing of the New Shares
The New Shares will be admitted to trading and official listing on Nasdaq Copenhagen A/S under the Company’s permanent ISIN-code (DK0011048619), with the expected first day of trading being April 16, 2020.
Share capital and votes following the Offering
BioPorto’s share capital has been increased by DKK 24,992,053 as a result of the Offering. Accordingly, BioPorto’s share capital now amounts to DKK 199,936,428 divided into 199,936,428 shares of nominally DKK 1 each, equivalent to 199,936,428 votes.
The Company’s articles of association has been updated to reflect the capital increase and are available on www.bioporto.com.
For further information, please contact:
Peter Mørch Eriksen, CEO
Ole Larsen, CFO
Telephone +45 4529 0000, e-mail: investor@bioporto.com
About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].
Legal disclaimer
The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, South Africa, Australia or Japan. This announcement and the information it contains is not a prospectus and does not constitute an offer of securities for sale nor a solicitation of any offer to buy any securities issued by BioPorto A/S in the United States or any other jurisdiction where such offer, solicitation or sale would be unlawful. This announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions.
Attachment
